LT2506868T - Faktoriaus viii-fc chimeriniai ir hibridiniai polipeptidai ir jų panaudojimo būdai - Google Patents

Faktoriaus viii-fc chimeriniai ir hibridiniai polipeptidai ir jų panaudojimo būdai

Info

Publication number
LT2506868T
LT2506868T LTEP10835255.0T LT10835255T LT2506868T LT 2506868 T LT2506868 T LT 2506868T LT 10835255 T LT10835255 T LT 10835255T LT 2506868 T LT2506868 T LT 2506868T
Authority
LT
Lithuania
Prior art keywords
chimeric
methods
factor viii
hybrid polypeptides
polypeptides
Prior art date
Application number
LTEP10835255.0T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jennifer A. Dumont
Susan Low
Alan J. Bitonti
Glenn Pierce
Alvin Luk
Haiyan Jiang
Byron Mckinney
Matt Ottmer
Jurg Sommer
Karen Nugent
Lian Li
Robert Peters
Original Assignee
Bioverativ Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc. filed Critical Bioverativ Therapeutics Inc.
Publication of LT2506868T publication Critical patent/LT2506868T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LTEP10835255.0T 2009-12-06 2010-12-06 Faktoriaus viii-fc chimeriniai ir hibridiniai polipeptidai ir jų panaudojimo būdai LT2506868T (lt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26707009P 2009-12-06 2009-12-06
US28505409P 2009-12-09 2009-12-09
US30159210P 2010-02-04 2010-02-04
US36306510P 2010-07-09 2010-07-09
US37311310P 2010-08-12 2010-08-12
US41092910P 2010-11-07 2010-11-07
US41967610P 2010-12-03 2010-12-03
PCT/US2010/059136 WO2011069164A2 (en) 2009-12-06 2010-12-06 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

Publications (1)

Publication Number Publication Date
LT2506868T true LT2506868T (lt) 2018-02-26

Family

ID=44115536

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10835255.0T LT2506868T (lt) 2009-12-06 2010-12-06 Faktoriaus viii-fc chimeriniai ir hibridiniai polipeptidai ir jų panaudojimo būdai

Country Status (30)

Country Link
US (5) US9050318B2 (enExample)
EP (4) EP3326643B1 (enExample)
JP (8) JP5903048B2 (enExample)
KR (1) KR101770849B1 (enExample)
CN (1) CN102791285A (enExample)
AU (6) AU2010325787B2 (enExample)
BR (1) BR112012013502A2 (enExample)
CA (2) CA2782424C (enExample)
CO (1) CO6561782A2 (enExample)
CY (2) CY1119919T1 (enExample)
DK (1) DK2506868T3 (enExample)
EA (2) EA038618B1 (enExample)
ES (2) ES2659888T3 (enExample)
HR (2) HRP20180135T1 (enExample)
HU (1) HUE036233T2 (enExample)
IL (2) IL220204B (enExample)
LT (1) LT2506868T (enExample)
ME (1) ME02964B (enExample)
MX (3) MX336830B (enExample)
MY (1) MY159135A (enExample)
NO (1) NO2506868T3 (enExample)
NZ (2) NZ600709A (enExample)
PL (2) PL2506868T3 (enExample)
PT (2) PT2506868T (enExample)
RS (1) RS56957B1 (enExample)
SG (3) SG10201408049SA (enExample)
SI (1) SI2506868T1 (enExample)
SM (1) SMT201800099T1 (enExample)
WO (1) WO2011069164A2 (enExample)
ZA (1) ZA201204874B (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
BR122021021381B1 (pt) 2009-02-03 2023-05-16 Amunix Pharmaceuticals, Inc Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
NO2506868T3 (enExample) 2009-12-06 2018-04-14
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
HUE043763T2 (hu) 2011-07-08 2019-09-30 Bioverativ Therapeutics Inc VIII-as faktor kiméra és hibrid polipeptidek, és azok alkalmazási eljárásai
EA028914B1 (ru) * 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3682905T (lt) 2011-10-03 2022-02-25 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas
PT2791160T (pt) 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
NZ626945A (en) * 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
NZ627078A (en) * 2012-01-12 2016-07-29 Biogen Ma Inc Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
EA201491470A1 (ru) * 2012-02-15 2015-01-30 Амуникс Оперэйтинг Инк. Композиции фактора viii и способы получения и использования подобных
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10317376B2 (en) 2012-04-11 2019-06-11 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
MX381011B (es) 2012-07-11 2025-03-12 Bioverativ Therapeutics Inc Complejo del factor viii con xten y proteína del factor von willebrand, y sus usos.
HK1212882A1 (zh) 2012-07-25 2016-06-24 Bioverativ Therapeutics Inc. 血液因子的監測分析及其用途
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
EP2914293A4 (en) * 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
EP4223772A3 (en) 2013-02-15 2023-10-18 Bioverativ Therapeutics Inc. Optimized factor viii gene
PT3666283T (pt) * 2013-03-15 2022-09-13 Bioverativ Therapeutics Inc Formulações de polipéptido de fator viii
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
US10364288B2 (en) 2013-05-24 2019-07-30 Biogen Ma Inc. Anti-GPIIB/IIIA antibodies or uses thereof
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
GEP20186882B (en) * 2013-06-20 2018-07-25 Baxalta Inc Providing a pharmacokinetic drug dosing regime
KR102714760B1 (ko) * 2013-06-28 2024-10-11 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
WO2014210547A1 (en) * 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker
EP3027224B1 (en) 2013-07-31 2020-06-03 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
WO2015085276A1 (en) * 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
HUE066567T2 (hu) 2014-01-10 2024-08-28 Bioverativ Therapeutics Inc VIII-as faktor kimérafehérjék és alkalmazásuk
JP6609561B2 (ja) 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
WO2015148454A1 (en) * 2014-03-28 2015-10-01 Asklepios Biopharmaceutical, Inc. Optimized and modified factor viii genes for gene therapy
EP3134127B1 (en) 2014-04-25 2020-02-26 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
CA3126536C (en) 2014-10-14 2023-07-25 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
US11560418B2 (en) 2015-10-20 2023-01-24 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX fusion proteins
IL320404A (en) 2016-02-01 2025-06-01 Bioverativ Therapeutics Inc Effective Factor VIII genes
HUE065455T2 (hu) 2016-04-15 2024-05-28 Takeda Pharmaceuticals Co Eljárás és berendezés egy farmakokinetikai gyógyszer adagolási rendjének biztosítására
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
JP6877469B2 (ja) * 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
EA201990222A1 (ru) 2016-08-05 2019-07-31 МЕДИММЬЮН, ЭлЭлСи Антитела к o2 и пути их применения
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN109843917B (zh) 2016-10-19 2023-10-03 免疫医疗有限责任公司 抗o1抗体及其用途
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
CN108239151B (zh) * 2016-12-23 2020-07-03 海门晟斯生物制药有限公司 重组单链人FVIII-Fc融合蛋白及其应用
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
MX2019009063A (es) 2017-01-31 2019-10-21 Bioverativ Therapeutics Inc Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.
CA3099049A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
US20210155710A1 (en) 2018-06-05 2021-05-27 Amgen Inc. Modulating antibody dependent cellular phagocytosis
MX2021002792A (es) 2018-09-11 2021-05-12 Amgen Inc Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
US20200199626A1 (en) 2018-12-06 2020-06-25 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
CN114007637A (zh) 2019-06-19 2022-02-01 比奥维拉迪维治疗股份有限公司 用于治疗血友病和低骨矿物质密度的重组因子viii-fc
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
CA3183557A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
KR20250005425A (ko) * 2022-04-28 2025-01-09 조인트 스탁 컴퍼니 "바이오케드" Fviii-bdd 및 이종의 신호 펩타이드에 기반한 융합 단백질을 인코딩하는 단리된 핵산
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235881A (en) * 1978-12-04 1980-11-25 Cort Joseph H Method for producing high potency factor VIII
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
ATE87663T1 (de) 1986-01-03 1993-04-15 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
AU2001274809A1 (en) * 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2301624T3 (es) * 2001-02-05 2008-07-01 Novo Nordisk Health Care Ag Uso combinado de polipeptidos de factor vii y polipeptidos de factor viii.
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP2298347B1 (en) 2003-05-06 2015-09-30 Biogen Hemophilia Inc. Clotting factor chimeric proteins for treatment of a hemostatic disorder
EP1644039B1 (en) 2003-06-19 2014-10-01 Genentech, Inc. Compositions and methods for treating coagulation related disorders
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
MX392760B (es) 2004-11-12 2025-03-24 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007103515A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
CA2715465C (en) * 2008-02-27 2017-03-21 Novo Nordisk A/S Conjugated factor viii molecules
US8800831B2 (en) 2009-08-19 2014-08-12 Larry A. Gray Multi-purpose rack and method thereof
BR122021021381B1 (pt) 2009-02-03 2023-05-16 Amunix Pharmaceuticals, Inc Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
CA2756197A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
NO2506868T3 (enExample) 2009-12-06 2018-04-14
HUE043763T2 (hu) * 2011-07-08 2019-09-30 Bioverativ Therapeutics Inc VIII-as faktor kiméra és hibrid polipeptidek, és azok alkalmazási eljárásai
NZ627078A (en) * 2012-01-12 2016-07-29 Biogen Ma Inc Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
PT3666283T (pt) * 2013-03-15 2022-09-13 Bioverativ Therapeutics Inc Formulações de polipéptido de fator viii
JP6083911B2 (ja) 2014-12-19 2017-02-22 花王株式会社 吸収性物品

Also Published As

Publication number Publication date
CA2782424A1 (en) 2011-06-09
JP6385410B2 (ja) 2018-09-05
EA201290443A1 (ru) 2013-06-28
CA3121739A1 (en) 2011-06-09
US9241978B2 (en) 2016-01-26
JP2025083451A (ja) 2025-05-30
AU2010325787B2 (en) 2016-05-12
PT3326643T (pt) 2021-07-12
JP2023071969A (ja) 2023-05-23
JP2022051964A (ja) 2022-04-01
IL220204A0 (en) 2012-07-31
KR20120129882A (ko) 2012-11-28
JP2013512678A (ja) 2013-04-18
EP2506868A4 (en) 2013-07-24
HK1253887A1 (en) 2019-07-05
EP4382170A2 (en) 2024-06-12
EP2506868A2 (en) 2012-10-10
JP5903048B2 (ja) 2016-04-13
AU2016213822B2 (en) 2017-08-31
MX2012006347A (es) 2012-10-03
AU2010325787A8 (en) 2012-07-19
WO2011069164A3 (en) 2011-07-28
NZ703153A (en) 2015-02-27
SMT201800099T1 (it) 2018-03-08
AU2024227757A1 (en) 2024-11-21
IL260769B (en) 2020-03-31
US9050318B2 (en) 2015-06-09
KR101770849B1 (ko) 2017-09-05
EP3326643B1 (en) 2021-04-07
JP2018024706A (ja) 2018-02-15
JP7244688B2 (ja) 2023-03-22
US20190262429A1 (en) 2019-08-29
CY1124888T1 (el) 2023-01-05
AU2017268648B2 (en) 2019-01-31
US20130274194A1 (en) 2013-10-17
EA038618B1 (ru) 2021-09-23
JP6062459B2 (ja) 2017-01-18
HUE036233T2 (hu) 2018-06-28
NZ600709A (en) 2015-01-30
US20220265780A1 (en) 2022-08-25
CA2782424C (en) 2021-07-27
JP2017025098A (ja) 2017-02-02
AU2021202912A1 (en) 2021-06-03
US11266720B2 (en) 2022-03-08
MX353233B (es) 2018-01-08
BR112012013502A2 (pt) 2017-01-10
AU2021202912B2 (en) 2024-08-01
EP3326643A1 (en) 2018-05-30
SG10201408049SA (en) 2015-02-27
HRP20211010T1 (hr) 2021-09-17
AU2019202969A1 (en) 2019-05-16
MX382693B (es) 2025-03-13
PL3326643T3 (pl) 2021-10-25
CY1119919T1 (el) 2018-06-27
DK2506868T3 (da) 2018-01-29
US20130108629A1 (en) 2013-05-02
JP6641340B2 (ja) 2020-02-05
AU2016213822A1 (en) 2016-09-01
ME02964B (me) 2018-07-20
EP4382170A3 (en) 2024-09-04
SG10201907152YA (en) 2019-09-27
HRP20180135T1 (hr) 2018-04-06
CO6561782A2 (es) 2012-11-15
AU2017268648A1 (en) 2017-12-21
EP3906937A1 (en) 2021-11-10
PT2506868T (pt) 2018-02-23
WO2011069164A2 (en) 2011-06-09
IL220204B (en) 2018-08-30
EA025416B1 (ru) 2016-12-30
US20160199455A1 (en) 2016-07-14
NO2506868T3 (enExample) 2018-04-14
ES2880038T3 (es) 2021-11-23
JP2020019821A (ja) 2020-02-06
CN102791285A (zh) 2012-11-21
EP2506868B1 (en) 2017-11-15
SI2506868T1 (en) 2018-04-30
ES2659888T3 (es) 2018-03-19
EA201691109A1 (ru) 2017-01-30
AU2010325787A1 (en) 2012-07-12
MX336830B (es) 2016-02-03
RS56957B1 (sr) 2018-05-31
PL2506868T3 (pl) 2018-06-29
SG181130A1 (en) 2012-07-30
ZA201204874B (en) 2016-06-29
JP2015083608A (ja) 2015-04-30
MY159135A (en) 2016-12-15
AU2010325787A2 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
IL260769B (en) Factor viii–fc chimeric and hybrid polypeptides and methods of using them
IL271870B (en) Factor viii chimeric and hybrid polypeptides and methods of using them
IL261147A (en) Methods for purification of polypeptides
SG184289A1 (en) Novel peptides and methods for their preparation and use
PL2590993T3 (pl) Polipeptydy
IL222027A (en) Peptides and their use
GB0916576D0 (en) Polypeptides and uses thereof
GB0916578D0 (en) Polypeptides and uses thereof
EP2580231A4 (en) PEPTIDES, CONSTRUCTIONS AND USES THEREOF
ZA201200167B (en) Methods of generating hybrid/chimeric cells, and uses thereof
GB0905790D0 (en) Novel polypeptides and use thereof
ZA201007681B (en) Cd4-related polypeptides and methods of use
GB201010202D0 (en) Fusion polypeptides